Radiolabelling and preclinical characterisation of [89Zr]Zr-Df-ATG-101 bispecific to PD-L1/4–1BB
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Radiolabelling and preclinical characterisation of [89Zr]Zr-Df-ATG-101 bispecific to PD-L1/4–1BB ; day:11 ; month:5 ; year:2024 ; pages:1-13
European journal of nuclear medicine and molecular imaging ; (11.5.2024), 1-13
- Urheber
-
Cao, Zhipeng
Wichmann, Christian Werner
Burvenich, Ingrid Julienne Georgette
Osellame, Laura Danielle
Guo, Nancy
Rigopoulos, Angela
O’Keefe, Graeme Joseph
Scott, Fiona Elizabeth
Lorensuhewa, Nirmal
Lynch, Kevin Patrick
Scott, Andrew Mark
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00259-024-06742-6
- URN
-
urn:nbn:de:101:1-2407221026201.527125907471
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cao, Zhipeng
- Wichmann, Christian Werner
- Burvenich, Ingrid Julienne Georgette
- Osellame, Laura Danielle
- Guo, Nancy
- Rigopoulos, Angela
- O’Keefe, Graeme Joseph
- Scott, Fiona Elizabeth
- Lorensuhewa, Nirmal
- Lynch, Kevin Patrick
- Scott, Andrew Mark
- SpringerLink (Online service)
Ähnliche Objekte (12)
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Bispecific antibodies
Bispecific antibodies
A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
ATG-Drängrabenfräse
ATG CRU
Transportverträge ATG
ATG- Drängrabenfräse
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Bispecific antibodies
Bispecific antibodies
A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
ATG-Drängrabenfräse
ATG CRU
Transportverträge ATG
ATG- Drängrabenfräse
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Bispecific antibodies
Bispecific antibodies
A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
ATG-Drängrabenfräse
ATG CRU
Transportverträge ATG